Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population
This study has been completed.
Sponsor:
Sanofi-Aventis
Information provided by:
Sanofi-Aventis
ClinicalTrials.gov Identifier:
NCT00847834
First received: February 18, 2009
Last updated: September 14, 2009
Last verified: September 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To analyse the control rate of irbesartan/hydrochlorothiazide(HCTZ) (COAPROVEL) in the treatment of patients with mild to moderate primary hypertension.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Irbesartan 150mg / Hydrochlorothiazide 12.5mg Drug: Irbesartan 150mg |
Phase 4 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Multi-center Open Label, Non-comparative Observational Study of Irbesartan-Hydrochlorothiazide in the Treatment of Hypertension in Chinese Population |
Resource links provided by NLM:
Further study details as provided by Sanofi-Aventis:
Primary Outcome Measures:
- Proportion of patients who reach a diastolic blood pressure <85 mmHg [ Time Frame: At 2, 4 and 8 weeks ] [ Designated as safety issue: No ]
Enrollment: | 968 |
Study Start Date: | December 2003 |
Primary Completion Date: | June 2004 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1
4 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by:
|
Drug: Irbesartan 150mg / Hydrochlorothiazide 12.5mg
Once a day
Drug: Irbesartan 150mg
Once a day
|
Experimental: 2
2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by 2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg followed by:
|
Drug: Irbesartan 150mg / Hydrochlorothiazide 12.5mg
Once a day
Drug: Irbesartan 150mg
Once a day
|
Eligibility
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Systolic blood pressure < 180 mmHg
- 90 mmHg ≤ Diastolic blood pressure < 110 mmHg
Exclusion criteria:
- Pregnancy or lactation. Women of child bearing potential (not post-menopausal) should be using a reliable contraceptive method
- Known or suspected secondary hypertension (e.g., coarctation of aorta, renovascular stenosis, etc.)
- Presence of clinically significant ventricular or supraventricular arrhythmias, or second or third degree atrioventricular block, or sick sinus syndrome
- ALAT[SGPT]>2 times of upper limit,
- ASAT[SGOT]>2 times of upper limit
- Patients with known renal disease
- Serum potassium > normal upper limit
- Uncontroled BD(FBG>10mmol/L or PBG>12.22mmol/L)
- Patients treated with tricyclic antidepressants
- Clinical hematological disease.
- Patients with a history of irbesartan, or hydrochlorothiazide sensitivity defined as irbesartan, or hydrochlorothiazide discontinuation due to medically significant adverse effects.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 26, 2012
No publications provided
Responsible Party: | Medical Affairs Study Director, sanofi-aventis |
ClinicalTrials.gov Identifier: | NCT00847834 History of Changes |
Other Study ID Numbers: | L_9292 |
Study First Received: | February 18, 2009 |
Last Updated: | September 14, 2009 |
Health Authority: | China: State Food and Drug Administration |
Additional relevant MeSH terms:
Hypertension Vascular Diseases Cardiovascular Diseases Hydrochlorothiazide Irbesartan Diuretics Natriuretic Agents Physiological Effects of Drugs Pharmacologic Actions |
Sodium Chloride Symporter Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Antihypertensive Agents Cardiovascular Agents Therapeutic Uses Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists |
ClinicalTrials.gov processed this record on September 26, 2012